Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma

ESMO Daily Reporter·Mar 13

This story is reported by ESMO Daily Reporter. Read what other outlets are saying below, then open the original report for full details.